Get complete Patent Opposition Report for Immatics Biotechnologies

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore Immatics Biotechnologies's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3236985Sep 7, 2022Novel Peptides And Combination Of Peptides For Use In Immunotherapy Against Hepatocellular Carcinoma (Hcc) And Other Cancers1